EARLY RHEUMATOID ARTHRITIS: CURRENT ASPECTS OF ITS DIAGNOSIS AND TREATMENT
https://doi.org/10.14412/1996-7012-2010-590
Abstract
Progression of rheumatoid arthritis (RA) leads to the generalization of a pathological process, by involving new joints and extra-articular structures,
the formation of irreversible changes, and resistance to performed therapy. The most favorable conditions for its treatment are available
at the onset of the disease in the patients who have not received basic anti-inflammatory therapy. Therefore the solution of practical issues of
medical care to patients with early-stage RA is quite urgent. It is necessary to decide as soon as possible whether basic anti-inflammatory drugs
(BAIDs) should be used in patients with verified RA or at real risk for its development. Preference is usually given to conventional BAIDs at the
first stage of therapy. Till recently methotrexate (MT) has been the gold standard treatment of such patients. However, the latest guidelines of
the American College of Rheumatology for the use of biological and non-biological BAIDs recommend that MT of leflunomide (LF) should be
given at a physician's discretion. The standard scheme for using LF in graded doses makes it possible to provide the therapeutic blood concentration
of the drug just within the first week of therapy and a noticeable clinical improvement within the first month. So LF acts much more rapidly
than other conventional BAIDs and may be of particular interest in treating RA.
the formation of irreversible changes, and resistance to performed therapy. The most favorable conditions for its treatment are available
at the onset of the disease in the patients who have not received basic anti-inflammatory therapy. Therefore the solution of practical issues of
medical care to patients with early-stage RA is quite urgent. It is necessary to decide as soon as possible whether basic anti-inflammatory drugs
(BAIDs) should be used in patients with verified RA or at real risk for its development. Preference is usually given to conventional BAIDs at the
first stage of therapy. Till recently methotrexate (MT) has been the gold standard treatment of such patients. However, the latest guidelines of
the American College of Rheumatology for the use of biological and non-biological BAIDs recommend that MT of leflunomide (LF) should be
given at a physician's discretion. The standard scheme for using LF in graded doses makes it possible to provide the therapeutic blood concentration
of the drug just within the first week of therapy and a noticeable clinical improvement within the first month. So LF acts much more rapidly
than other conventional BAIDs and may be of particular interest in treating RA.
References
1. <div><p>Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol Review 2009 Mar;21(2):118-23.</p><p>Furst D.E. Window of opportunity. J Rheumatol 2004 Sep;31(9):1677-9.</p><p>Mitchell K.L., Pisetsky D.S. Early rheumatoid arthritis. Curr Opin Rheumatol Review 2007 May;19(3):278-83.</p><p>Nell V.P., Machold K.P., Eberl G. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004 Jul;43(7):906-14.</p><p>Machold K.P., Nell V., Stamm T. et al. Early rheumatoid arthritis. Curr Opin Rheumatol Review 2006 May;18(3):282-8.</p><p>Каратеев Д.Е., Лучихина Е.Л., Тюрина Л.Н. и др. Возможности ранней диагностики ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Тер арх 2008;5:8-13.</p><p>Kiely P., Williams R., Walsh D. et al. Early Rheumatoid Arthritis Network. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology (Oxford) 2009 Jan;48(1):57-60.</p><p>Combe B., Landewe R., Lukas C. et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007 Jan;66(1):34-45.</p><p>Каратеев Д.Е., Олюнин Ю.А. О классификации ревматоидного артрита. Научпрактич ревматол 2008;1:5-16.</p><p>Stanich J.A., Carter J.D., Whittum-Hudson J. et al. Rheumatoid arthritis: disease or syndrome? Open Access Rheumatology Research and Reviews 2009;1:179-92.</p><p>Guerne P.A., Weisman M.H. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am J Med Review 1992 Oct;93(4):451-60.</p><p>Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis Review 2002 Apr;61(4):290-7.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr Rheum 2008 Jun 15;59(6):762-84. 14.</p><p>Клинические рекомендации. Ревматология. Под ред. акад. РАМН Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010;738 с.</p><p>Smolen J.S., Kalden J.R., Scott D.L. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999 Jan 23;353(9149):259-66.</p><p>Strand V., Cohen S., Schiff M. et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999 Nov 22;159(21):2542-50.</p><p>Emery P., Breedveld F.C., Lemmel E.M. et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun;39(6):655-65.</p><p>Siva C., Eisen S.A., Shepherd R. et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthr Rheum 2003 Dec 15;49(6):745-51.</p><p>Pisoni L., Murgo A., Paresce E. et al. Effectiveness and safety of leflunomide in the clinical practice. A different experience. Clin Exp Rheumatol 2007 Jan-Feb;25(1):115; author reply 116.</p><p>White D.H., Lynskey N.V., Jones P.B. Leflunomide use in New Zealand. A national prospective post-marketing study. Intern Med J 2009 Feb;39(2):95-102.</p><p>Балабанова Р.М., Олюнин Ю.А., Насонов Е.Л. Регистр пациентов с ранним ревматоидным артритом, впервые получающих монотерапию лефлуномидом (Аравой) в течение 48 недель (предварительные результаты). IV Национальный конгресс терапевтов. Тез. докл. М., 2009;57.</p></div><br />
Review
For citations:
Olyunin YA, Olyunin YA. EARLY RHEUMATOID ARTHRITIS: CURRENT ASPECTS OF ITS DIAGNOSIS AND TREATMENT. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(1):65-70. (In Russ.) https://doi.org/10.14412/1996-7012-2010-590
Views:
4763
Email this article 